



Ref: SEC/SE/2021- 22
Date: February 02, 2022

Scrip Symbol: NSE– DABUR, BSE Scrip Code: 500096

To,
Corporate Relation Department
BSE Ltd
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001

National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor
Plot No. C/1, G Block Bandra – Kurla Complex
Bandra (E), Mumbai – 400051

Sub: Press Release

Dear Sir,


In compliance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose a copy of Press Release being issued by the company today for your records.

This is for your information and records.

Thanking You,


Yours faithfully,

For **Dabur India Limited**


(A K Jain)

Executive V P (Finance) and Company Secretary

Encl: as above



Dabur Q3 Consol. Revenue Up 8% at Rs 2,942 Crore

New Delhi, February 02, 2022: India's leading Science-based Ayurveda major **Dabur India Ltd** today reported an **8% growth in Consolidated Revenue for the Quarter ended December 31, 2021** on a very high base of the previous year, with the **9-month Consolidated Revenue reporting a 16% growth year-on-year**.

The Board of Directors of Dabur India Ltd met here today to consider the unaudited financial results of the company for the third quarter of 2021-22.

Dabur India Ltd braved the heavy inflationary pressures, a significant moderation in industry growth and dip in overall consumer sentiments to deliver a competitive and healthy Consolidated Revenue growth of 8% at Rs 2,942 Crore in the third quarter of 2021-22 financial year, up from Rs 2,729 Crore in the same quarter a year ago. Consolidated Revenue for the quarter reported a 2-year CAGR of 11.8%, reflecting the remarkable agility and resilience the business continues to demonstrate even in a tough market.

Operating Profit for the quarter reported a strong 9.3% growth ahead of the Topline growth. Consolidated Net Profit for the third quarter was up 2.3% to cross the Rs 500 Crore mark for the second time in a row and ended at Rs 503 Crore, as against Rs 492 Crore a year ago. Consolidated Net Profit for the 9-month period marked a 10% growth, while the India FMCG Business reported a 13% Volume growth for the 9-month period.

"The overall operating environment remained challenging throughout the quarter with unprecedented inflation of 13% and subdued consumer sentiments. We have mitigated the impact of inflation partially through calibrated price increases and cost-saving initiatives. Despite these macro-economic headwinds, we remained focused on rolling our consumer-centric innovation that expanded our total addressable market, besides gaining market share across 100% of our product portfolio, which is unprecedented. Our investments in distribution footprint expansion in rural India helped drive growth even in a challenging environment with rural demand for Dabur outpacing urban demand by 500bps," **Dabur India Ltd Chief Executive Officer Mr. Mohit Malhotra said.**

"There has been a marked revival in discretionary spending by consumers, which helped the Home & Personal care business grow by 8.4%. While our Healthcare portfolio was impacted due to the high base of the previous year and a marked drop in demand for COVID-contextual products, this business reported a 2-year CAGR of 11.4%. Excluding the COVID-contextual range of Chyawanprash and Honey, **our domestic FMCG Volume Growth stood at 8% for the third quarter," Mr. Mohit Malhotra said.**

Going forward, Dabur will continue to plough heavy investments behind its Power Brands, coupled with investment in expanding the rural footprint and enhancing the go-to-market approach to drive sustainable, profitable growth.

Category Growth

Dabur's Foods & Beverages business continued to be the outperformer in Q3, growing by 38%. "Dabur's Foods business under the Hommade brand with a range of Ready-to-Eat and Ready-to-Cook products, will become a Rs 100 Crore business by the end of the 2021-22 financial year," Mr. Malhotra said.

The Home Care business ended the quarter with an 19% growth while the Skin Care business, excluding the Sanitiser range, grew by 20% during the quarter. The Digestives business grew by 12.2% while the Hair Care category reported an 8.4% growth, riding on an over 21% surge in Shampoo business. Dabur's Toothpaste business also reported a strong industry-leading 8.1% growth while the Ayurvedic Ethicals business grew by 8.3% during the quarter.

With the business fundamentals remaining strong, Dabur posted handsome market share gains across the entire portfolio, led by a 514bps improvement in Juices & Nectars market share to the highest-ever share of 64.3%. Dabur's share in the Chyawanprash category improved by 200bps to 63.6%. In the Honey market, Dabur reported a market share gain of 180bps. Dabur also reported a 90bps market share gain in Hair Oils, with our share of the pure Coconut Oil market increasing 120bps. Dabur's share increased by 50bps in the Toothpaste market and 40bps in the Shampoo category. Dabur also reported a 50bps increase in Air Freshener market share and a 40bps gain in mosquito repellent cream category.

International Business

Dabur's International Business reported a growth of 8.7% in Constant Currency terms. The UK & EU business grew by 21.5%, while the Nepal business was up 17%. The US business posted a growth of 16%, while the Turkey business reported a 14.6% growth and Egypt grew by 13%.

About Dabur India Ltd

Dabur India Limited is one of India's leading FMCG Companies. Building on a legacy of quality and experience for 137 years, Dabur is today India's most trusted name and one of the world's largest Ayurvedic and Natural Health Care Company. Dabur India's FMCG portfolio today includes eight distinct Power Brands: **Dabur Chyawanprash, Dabur Honey, Dabur Honitus, Dabur Pudinhara and Dabur Lal Tail** in the Healthcare space; **Dabur Amla and Dabur Red Paste** in the Personal care category; and **Réal** in the Foods & Beverages category.

For further information, Contact:

Byas Anand

Corporate Communications

Dabur India Ltd

Ph.: +91-9811994902

